Immune activators have been found to induce antitumor immune response via DC activation (Kuhn et al., 2013) followed by CD8+ T-cell priming (Kuhn et al., 2015), and this approach is likely only functional when acting on DCs that already acquired tumor antigens, such as tumor-associated DCs. This evidence concerns the gene CD8A and neoplasm.